Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar

 April 9, 2026

Big Molecule Watch

On March 30, 2026, Teva Pharmaceutical Industries Ltd.

RegulatoryRead full story

Post navigation

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk →
← Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com